Lattice Launches Industry-First PQC-Ready FPGA Family: MachXO5-NX TDQ
13.10.2025 15:00:00 CEST | Business Wire | Press Release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today introduced the Lattice MachXO5™-NX TDQ family, the industry’s first secure control FPGAs with full Commercial National Security Algorithm (CNSA) 2.0-compliant post-quantum cryptography (PQC) support. Built on the award-winning Lattice Nexus™ platform, MachXO5-NX TDQ FPGAs deliver unmatched security, reliability, and flexibility for Computing, Communications, Industrial, and Automotive applications as the threat of quantum-enabled cyberattacks rises.
“Quantum computing advances increase the urgency to adopt quantum-resistant security across every industry,” said Esam Elashmawi, Chief Strategy and Marketing officer, Lattice Semiconductor. “With MachXO5-NX TDQ, Lattice is first to market with a secure control FPGA family that not only meets today’s security mandates but also delivers crypto-agility and hardware root of trust to future-proof our customers’ infrastructure against evolving threats.”
The Lattice MachXO5-NX TDQ FPGA family equips customers with:
- Full Suite of CNSA 2.0 Compliant PQC
- First and only complete CNSA 2.0 and National Institute of Standards and Technology (NIST)-approved PQC algorithms (LMS, XMSS, ML-DSA, ML-KEM, AES256-GCM, SHA2, SHA3, SHAKE) for robust protection against quantum threats
- Authenticated and/or encrypted bitstream ensuring data integrity and protection against unauthorized access with ML-DSA, LMS, XMSS, AES256
- Unique, patent pending crypto-agility with in-field algorithm update capability and anti-rollback version protection to enable ongoing alignment with evolving standards
- Secure bitstream key management with revokable root keys and sophisticated key hierarchy for both PQC and classical keys
- Advanced Cryptography
- Full complement of advanced symmetric and classical asymmetric cryptographic algorithms (AES-CBC/GCM 256 bit, ECDSA-384/521, SHA-384/512, RSA 3072/4096 bit) for bitstream and user data protection
- Device Identifier Composition Engine (DICE), Security Protocol and Data Model (SPDM), and Lattice SupplyGuard™ capable, providing attestation and secure lifecycle/supply chain management for future-proof, end-to-end security
- Hardware Root of Trust (RoT)
- Trusted single-chip boot with integrated flash
- Unique device secret (UDS) ensuring distinct device identity
- Integrated non-volatile configuration memory and user flash memory (UFM) with flexible partitioning and secure locking
- Comprehensive locking control of programming interface (SPI, JTAG), providing complete protection
- Side Channel Attack (SCA) resiliency and NIST Cryptographic Algorithm Validation Program (CAVP) compliant algorithms
Lattice also expanded its RoT-enabled Lattice MachXO5-NX device family with new MachXO5-NX TD devices that offer new density and package options. These new Lattice MachXO5-NX TDQ and MachXO5-NX TD FPGA devices are available and have shipped to industry-leading Communications and Compute customers, and are supported by the latest release of Lattice Radiant™ design software.
Experience Lattice PQC-Ready Innovation at OCP Global Summit
Lattice will showcase live demonstrations of its latest FPGA solutions including the MachXO5-NX TDQ for secure, AI-optimized datacenter infrastructure at the OCP Global Summit, taking place Oct. 14–16, 2025 at the San Jose Convention Center, San Jose, Calif. Visit Lattice at Booth #A23 to experience future-ready security, including CNSA 2.0-compliant PQC, intelligent connectivity, and power-efficient AI acceleration.
Supporting Resources
- For more information about Lattice MachXO5-NX TDQ, visit product webpage, read the launch blog, or download the white paper here.
- For more information about Lattice’s OCP Global Summit participation, read the event announcement.
- For more information about Lattice, please visit https://www.latticesemi.com
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.
For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, X, Facebook, YouTube, WeChat, or Weibo.
Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013522544/en/
Contacts
MEDIA CONTACT:
Sophia Hong
Lattice Semiconductor
503-268-8786
Sophia.Hong@latticesemi.com
INVESTOR CONTACT:
Rick Muscha
Lattice Semiconductor
408-826-6000
Rick.Muscha@latticesemi.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom